Plexxikon Inc.
91 Bolivar Drive
Berkeley
California
94710
United States
Tel: 510-647-4000
Fax: 510-548-8014
Website: http://www.plexxikon.com/
Email: info@plexxikon.com
56 articles about Plexxikon Inc.
-
Plexxikon, which was acquired by Daiichi Sankyo, and Novartis have agreed to settle a patent case involving the cancer drug Tafinlar and its sale in the U.S.
-
Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.
-
Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical Stage BRAF Inhibitor
6/3/2020
Novellus, a precision-oncology drug development company, announced today that it has entered into an exclusive worldwide license agreement with Plexxikon, a member of the Daiichi Sankyo Group, for PLX8394, its clinical-stage oncology drug candidate which targets the BRAF protein. PLX8394 is currently completing a Ph
-
Daiichi Sankyo and Plexxikon Suspend Phase III Trial of Drug for Rare Tendon Cancer
10/19/2016
-
FDA Approves Daiichi Sankyo, Plexxikon's Cobimetinib In Combination With Zelboraf for Advanced Melanoma Patients
11/11/2015
-
Daiichi Sankyo and Bay Area’s Plexxikon Inc. Win Breakthrough Tag for Pexidbartini
11/2/2015
-
Daiichi Sankyo, Plexxikon Inc.'s Rare Disease Drug Shows Promise in Phase I Study
7/30/2015
-
Plexxikon Inc. And Merck & Co. To Collaborate On Combination Study Evaluating Investigational Immuno-Oncology Regimen
5/7/2015
-
Plexxikon Inc. And Quantumleap Healthcare Collaborative Announce Selection Of PLX3397 For I-SPY 2 TRIAL In Breast Cancer
12/11/2014
-
OncoSec Medical Inc. And Plexxikon Inc. Collaborate To Explore Combination Immunotherapy In Preclinical Tumor Studies
11/18/2014
-
Plexxikon Inc. Announces Promising Preliminary PLX3397 Phase 1 Extension Data In Patients With Pigmented Villonodular Synovitis (PVNS)
5/15/2014
-
Plexxikon Inc. Announces PLX3397 Data Presentations At American Society of Clinical Oncology 2014 Annual Meeting
5/15/2014
-
Plexxikon Inc. Taps New CEO, COO
5/31/2013
-
Plexxikon Inc. Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients
11/9/2012
-
Plexxikon Inc. Announces European Approval of Zelboraf® for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
2/21/2012
-
Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood Cancer
12/13/2011
-
Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood Cancer
12/12/2011
-
Plexxikon Inc. Novel Agents Aim to Address Cancer Treatment in New Ways
11/14/2011
-
Plexxikon Inc. Announces Combination Trials for Vemurafenib in Melanoma
6/2/2011
-
Plexxikon Inc. Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at American Society of Clinical Oncology 2011 Annual Meeting
5/18/2011